Johnson & Johnson said that Phase1/2 trial data showed that a single dose of its COVID-19 vaccine candidate, JNJ-78436735, induced a “strong” neutralizing …
Johnson & Johnson shares are up 2.3% in Wednesday’s pre-market trading after the healthcare company announced that it is kicking off with a …
Johnson & Johnson will kick off Phase 2 trials of its COVID-19 vaccine candidate in Spain on Monday, according to the trial’s unit …
Johnson & Johnson announced Tuesday that the European Commission (EC) has approved an extended use of imbruvica (ibrutinib) in combination with rituximab for …
Johnson & Johnson and Pfizer have been in the news for the development of potential vaccines for COVID-19. According to the latest update, …
Johnson & Johnson (JNJ) is aiming to test its coronavirus vaccine in up to 60,000 volunteers in a Phase 3 clinical trial set …
The U.S.
Johnson & Johnson (JNJ) has agreed to buy Momenta Pharma (MNTA), a biotech focused on discovering and developing novel biologic therapeutics for rare …
The European Commission announced Thursday that it has concluded exploratory talks with US pharmaceutical company Johnson & Johnson to secure the initial purchase …
Johnson & Johnson (JNJ) initiated first-in-human safety trials of its COVID-19 vaccine candidate after a single dose in pre-clinical studies showed “robust protection”. …
